Prime Medicine, Inc. (NASDAQ:PRME – Get Free Report)’s stock price reached a new 52-week high during trading on Wednesday . The company traded as high as $5.63 and last traded at $5.54, with a volume of 3228599 shares trading hands. The stock had previously closed at $5.32.
Analysts Set New Price Targets
Separately, Wall Street Zen cut shares of Prime Medicine from a “hold” rating to a “sell” rating in a research note on Tuesday, September 2nd.
Read Our Latest Research Report on Prime Medicine
Prime Medicine Trading Up 19.3%
About Prime Medicine
We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology.
Further Reading
- Five stocks we like better than Prime Medicine
- Utilities Stocks Explained – How and Why to Invest in Utilities
- General Dynamics Hits New Highs: Why It Might Keep Climbing
- Buy P&G Now, Before It Sets A New All-Time High
- Nike’s Turnaround: If the Shoe Fits, Buy It!
- Investing in Travel Stocks Benefits
- NVIDIA Breaks Out to New Highs: What Comes Next?
Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
